Speaking on improving accessibility and innovation with the new role, Samir Mehta said, “COVID 19 has been a challenging time for the Indian pharmaceutical industry. However, the industry has risen to the challenges and ensured continuous supply of medicines to patients. The pandemic has further highlighted the significance of collaboration, access to affordable medicines and innovation to respond to the country’s healthcare needs. IPA will be collaborating with stakeholders to strengthen the accessibility of medicines and help in creating an innovation ecosystem that will be beneficial to the patients.”
Indian Pharmaceutical Alliance (IPA) represents 23 research based national pharmaceutical companies. Collectively, IPA companies account for over 85 per cent of the private sector investment in pharmaceutical research and development.
Talking about the new leadership role, Samina Hamied said “Pleased to receive this opportunity to play a pivotal role in shaping the healthcare ecosystem and unlocking significant growth opportunities. I am looking forward to working collaboratively with all stakeholders of the industry to ensure sustainable,resilient and agile